Inflammatory mediators in chronic heart failure: an overview.
Anker
Stefan D
SD
Department of Clinical Cardiology, Imperial College School of Medicine, National Heart & Lung Institute, London, UK. s.anker@imperial.ac.uk
von Haehling
Stephan
S
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000378:metabolism; D015815:Cell Adhesion Molecules / Q000502:physiology; D016207:Cytokines / Q000502:physiology; D000068800:Etanercept; D006333:Heart Failure / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D007962:Leukocytes / Q000276:immunology; D016131:Lymphocyte Subsets; D009205:Myocarditis / Q000276:immunology; D009569:Nitric Oxide / Q000502:physiology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D015815:Cell Adhesion Molecules; D016207:Cytokines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D002097:C-Reactive Protein; D000069285:Infliximab; D000068800:Etanercept